» Articles » PMID: 24333663

Flk2/Flt3 Promotes Both Myeloid and Lymphoid Development by Expanding Non-self-renewing Multipotent Hematopoietic Progenitor Cells

Overview
Journal Exp Hematol
Specialty Hematology
Date 2013 Dec 17
PMID 24333663
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Defining differentiation pathways is central to understanding the pathogenesis of hematopoietic disorders, including leukemia. The function of the receptor tyrosine kinase Flk2 (Flt3) in promoting myeloid development remains poorly defined, despite being commonly mutated in acute myeloid leukemia. We investigated the effect of Flk2 deficiency on myelopoiesis, focusing on specification of progenitors between HSC and mature cells. We provide evidence that Flk2 is critical for proliferative expansion of multipotent progenitors that are common precursors for all lymphoid and myeloid lineages, including megakaryocyte/erythroid (MegE) cells. Flk2 deficiency impaired the generation of both lymphoid and myeloid progenitors by abrogating propagation of their common upstream precursor. At steady state, downstream compensatory mechanisms masked the effect of Flk2 deficiency on mature myeloid output, whereas transplantation of purified progenitors revealed impaired generation of all mature lineages. Flk2 deficiency did not affect lineage choice, thus dissociating the role of Flk2 in promoting cell expansion and regulating cell fate. Surprisingly, despite impairing myeloid development, Flk2 deficiency afforded protection against myeloablative insult. This survival advantage was attributed to reduced cell cycling and proliferation of progenitors in Flk2-deficient mice. Our data support the existence of a common Flk2(+) intermediate for all hematopoietic lineages and provide insight into how activating Flk2 mutations promote hematopoietic malignancy by non-Flk2-expressing myeloid cells.

Citing Articles

Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets.

Bruno S, Borsi E, Patuelli A, Bandini L, Mancini M, Forte D Int J Mol Sci. 2024; 25(18).

PMID: 39337490 PMC: 11432296. DOI: 10.3390/ijms251810002.


Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of .

Levis M, Hamadani M, Logan B, Jones R, Singh A, Litzow M J Clin Oncol. 2024; 42(15):1766-1775.

PMID: 38471061 PMC: 11095884. DOI: 10.1200/JCO.23.02474.


Slow cycling and durable Flt3+ progenitors contribute to hematopoiesis under native conditions.

Solomon M, Song B, Govindarajah V, Good S, Arasu A, Hinton E J Exp Med. 2023; 221(1).

PMID: 37910046 PMC: 10620607. DOI: 10.1084/jem.20231035.


Hematopoietic stem cells and extramedullary hematopoiesis in the lungs.

Reichard A, Wanner N, Farha S, Asosingh K Cytometry A. 2023; 103(12):967-977.

PMID: 37807901 PMC: 10841540. DOI: 10.1002/cyto.a.24804.


Lineage tracking to reveal the fate of hematopoietic stem cells influenced by Flk2 multipotent progenitors after transplantation.

Wang Z, Jiang D, Vergel-Rodriguez M, Nogalska A, Lu R Exp Mol Med. 2023; 55(1):205-214.

PMID: 36639717 PMC: 9898540. DOI: 10.1038/s12276-022-00922-w.


References
1.
Hudak S, Hunte B, Culpepper J, Menon S, Hannum C, Thompson-Snipes L . FLT3/FLK2 ligand promotes the growth of murine stem cells and the expansion of colony-forming cells and spleen colony-forming units. Blood. 1995; 85(10):2747-55. View

2.
Langdon W . FLT3 signaling and the development of inhibitors that target FLT3 kinase activity. Crit Rev Oncog. 2012; 17(2):199-209. DOI: 10.1615/critrevoncog.v17.i2.50. View

3.
Yokota T, Oritani K, Butz S, Kokame K, Kincade P, Miyata T . The endothelial antigen ESAM marks primitive hematopoietic progenitors throughout life in mice. Blood. 2008; 113(13):2914-23. PMC: 2974489. DOI: 10.1182/blood-2008-07-167106. View

4.
Dosil M, Wang S, Lemischka I . Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol Cell Biol. 1993; 13(10):6572-85. PMC: 364716. DOI: 10.1128/mcb.13.10.6572-6585.1993. View

5.
Hudak S, Leach M, Xu Y, Menon S, Rennick D . Radioprotective effects of flk2/flt3 ligand. Exp Hematol. 1998; 26(6):515-22. View